CD8A and neoplasm: Based on the results from our flow cytometry analysisthat showed higher PD-1+CD8+TILs in STING agonist-treated tumours, we added anti-PD-1 antibody treatment toone arm of the study where mice were treated with a combination of carboplatin andSTING agonist.